1. Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, Efrati C, Franceschilli M,

2. Guida AM, Ingallinella S, Montagnese F, Sensi B, Siragusa L, Sica GS. Pathophysiology of

3. Crohn's disease inflammation and recurrence.Biol Direct. 2020 Nov 7;15(1):23.

4. Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di

5. Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J,

6. Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath VAn expert consensus to

7. standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies

8. in Crohn's disease. .Aliment Pharmacol Ther. 2018 Aug;48(3):347-357.

9. Биотерапевтический указатель, Heel. 2015. Под редакцией Ф. Ибрагимли.

10. Ding X, Kaminsky LS. Human extra hepatic cytochromes P450: function in xenobiotic

11. metobolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal

12. tracts. Annu Rev Pharmacol Toxicol 2003:43:149-173

13. Bressler JP, Olivi L, Cheong JH, Kim Y,Maerten A,Bannon D. Metal transporters in intestine

14. and brain:their involvement in metal-associated neurotoxicities. Hum Exp. Toxicol.

15. 2007:26(3);221-229

16. Bonini M, La Torre G, De cesare A, et al. A randomized clinicial trial of the effect of

17. Echinacea compositum S on the prophylaxis 0f post-operative infections. J prev /Med

18. Hygiene 2001:42:30-35

19. Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate